M
Markku Broas
Publications - 2
Citations - 681
Markku Broas is an academic researcher. The author has contributed to research in topics: Coronavirus. The author has an hindex of 2, co-authored 2 publications receiving 542 citations.
Papers
More filters
Journal ArticleDOI
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
Gianfranco Spiteri,James E Fielding,Michaela Diercke,C Campese,Vincent Enouf,Alexandre Gaymard,Antonino Bella,Paola Sognamiglio,María José Sierra Moros,Antonio Nicolau Riutort,Yulia V. Demina,Romain Mahieu,Markku Broas,Malin Bengnér,Silke Buda,Julia Schilling,Laurent Filleul,Agnes Lepoutre,C. Saura,Alexandra Mailles,Daniel Lévy-Bruhl,Bruno Coignard,Sibylle Bernard-Stoecklin,Sylvie Behillil,Sylvie van der Werf,Martine Valette,Bruno Lina,Flavia Riccardo,Emanuele Nicastri,Inmaculada Casas,Amparo Larrauri,Magdalena Salom Castell,Francisco Pozo,Rinat A. Maksyutov,Charlotte Martin,Marc Van Ranst,Nathalie Bossuyt,Lotta Siira,Jussi Sane,Karin Tegmark-Wisell,Maria Palmérus,Eeva Broberg,Julien Beauté,Pernille Jorgensen,Nick Bundle,Dmitriy Pereyaslov,Cornelia Adlhoch,Jukka Pukkila,Richard Pebody,Sonja J. Olsen,Bruno Christian Ciancio +50 more
TL;DR: In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020, and the first European cases are detailed, with among 38 cases studied, 21 were linked to two clusters in Germany and France, 14 were infected in China.
Journal ArticleDOI
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Anu Haveri,Teemu Smura,Suvi Kuivanen,Pamela Österlund,Jussi Hepojoki,Jussi Hepojoki,Niina Ikonen,Marjaana Pitkapaasi,Soile Blomqvist,Esa Rönkkö,Anu Kantele,Tomas Strandin,Hannimari Kallio-Kokko,Laura Mannonen,Maija Lappalainen,Markku Broas,Miao Jiang,Miao Jiang,Lotta Siira,Mika Salminen,Taneli Puumalainen,Jussi Sane,Merit Melin,Olli Vapalahti,Carita Savolainen-Kopra +24 more
TL;DR: The clinical picture and laboratory findings 3–23 days since the first symptoms are described, and neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.